Zura Bio LTD Form 4 insider transactions

Director Amit Munshi of Zura Bio Ltd. has acquired 117,000 share options at an exercise price of $2.76, vesting over one year.

Parvinder Thiara, a director at Zura Bio Ltd, acquired 117,000 share options on December 9, 2024, which vest over a one-year period.

Zura Bio Ltd. has granted share options to Sidhu Someit, vesting over a one-year period.

Zura Bio's CEO, Robert Lisicki, was granted 117,000 share options on December 9, 2024, vesting over one year.

Parvinder Thiara, a director at Zura Bio Ltd, disposed of 1,001,633 Class A Ordinary Shares in a private transaction on November 25, 2024.

Director Parvinder Thiara of Zura Bio Ltd. reports the disposal of 3,800,000 Class A Ordinary Shares in a private transaction on September 11, 2024.

Kiran Nistala, an officer of Zura Bio Ltd, files an amendment to a previously submitted Form 4 to correct the transaction code for a purchase of Class A ordinary shares.

Director Someit Sidhu of Zura Bio Ltd. sold 51,728 Class A ordinary shares at an average price of $3.87 on September 4, 2024.

Someit Sidhu, a director of Zura Bio Ltd, filed an amendment to a previous Form 4 to correct the transaction code for shares acquired in a private placement.

An amended SEC Form 4 reveals a correction to the transaction code for a Zura Bio director's acquisition of shares in a private placement.

Michael Howell, an officer of Zura Bio Ltd, files an amendment to a previously submitted Form 4 to correct the transaction code for a purchase of Class A ordinary shares.

Zura Bio Limited finalized its exchange offer and consent solicitation, leading to the exchange of a significant portion of its warrants and the planned exchange of remaining warrants for Class A ordinary shares.

Zura Bio reports high participation in its exchange offer and consent solicitation, paving the way for warrant amendment and simplification of its capital structure.

Michael Howell, Chief Scientific Officer of Zura Bio Ltd, reports the disposal of shares to cover tax obligations related to restricted stock units.

Zura Bio Limited reached a settlement agreement with its former CEO, Someit Sidhu, involving severance payments and accelerated vesting of stock options.

Zura Bio Limited has commenced an exchange offer and consent solicitation relating to its outstanding warrants to simplify its capital structure and reduce potential dilution.

Michael Howell, Chief Scientific Officer and Head of Translational Science at Zura Bio Ltd., acquired 295,000 employee share options on June 18, 2024.

Gary Whale, Chief Technology Officer of Zura Bio Ltd, reports the acquisition of 280,000 employee share options.

Kim Davis, Chief Legal Officer of Zura Bio Ltd., reports the acquisition of stock options for 420,000 Class A Ordinary Shares.

Verender S. Badial, CFO of Zura Bio Ltd, reports the acquisition of 420,000 employee share options.

Zura Bio Ltd's CEO, Robert Lisicki, reported the acquisition of 1,050,000 employee share options on June 18, 2024.

Kiran Nistala, Chief Medical Officer and Head of Development at Zura Bio Ltd., acquired stock options for 285,000 Class A Ordinary Shares on June 18, 2024.

Director Arnout Ploos van Amstel reports purchasing 80,000 Class A ordinary shares and disposing of 100,000 shares of Zura Bio Ltd.

Officer Michael Howell reports the acquisition of Zura Bio Ltd shares through a private placement and indirect ownership via Mountaineer Biosciences, Inc.

Kiran Nistala, Executive Vice President of Zura Bio Ltd, acquired 3,195 Class A ordinary shares through a private placement at $3.13 per share on April 22, 2024.

Director Amit Munshi acquired 159,744 Class A ordinary shares of Zura Bio Ltd at $3.13 per share, increasing his total holdings to 777,384 shares.

Director Someit Sidhu reports acquisition of Zura Bio shares through a private placement and indirect holdings.